EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease

A Bernardelli, E Carazzai, I Mion, N Serafin, I Ferrarini, M Krampera iD, C Visco

Hematological Oncology · 2026-05 · 44 (3)

DOI: 10.1002/hon.70194 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hematological Oncology, online erschienen am 27.04.2026. Verfasst von A Bernardelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: UOC di Ematologia e CTMO, DAI Medico Generale, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy. Hauptthemen laut MEDLINE: Leukemia, Hairy Cell, Agammaglobulinaemia Tyrosine Kinase, Pyrazoles, Pyrimidines. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hairy cell leukemia variant (HCL‐v) is a rare B‐cell malignancy with limited treatment options in relapsed or refractory settings. We describe the first reported case of chemo‐refractory HCL‐v successfully treated with zanubrutinib monotherapy. An 84‐year‐old man, previously refractory to rituximab and bendamustine, achieved early hematologic improvement and reduction in spleen size after starting zanubrutinib, with a sustained clinical and laboratory response at 17 months. A clinical study with ibrutinib has shown durable disease control in classic and variant HCL, supporting BTK inhibition as a therapeutic strategy. This case suggests zanubrutinib as a promising chemo‐free option for frail HCL‐v patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Hairy CellAgammaglobulinaemia Tyrosine KinasePyrazolesPyrimidinesProtein Kinase InhibitorsAntineoplastic AgentsHumansMaleAged, 80 and overPiperidines

Stichwörter der Autor:innen

BTK inhibitionhairy cell leukemia varianttargeted therapyzanubrutinib

Substanzen

Agammaglobulinaemia Tyrosine KinasePyrazolesPyrimidinesProtein Kinase InhibitorszanubrutinibBTK protein, humanAntineoplastic AgentsPiperidines

Autor:innen und Institutionen

  • UOC di Ematologia e CTMO, DAI Medico Generale, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine (DIMI), Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy.

ORCID-Profile: M Krampera

Zitieren

APA

Bernardelli, A., Carazzai, E., Mion, I., Serafin, N., Ferrarini, I., Krampera, M., & Visco, C. (2026). Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease. Hematological Oncology, 44(3). https://doi.org/10.1002/hon.70194

Vancouver

Bernardelli A, Carazzai E, Mion I, Serafin N, Ferrarini I, Krampera M, et al. Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease. Hematological Oncology. 2026;44(3). doi:10.1002/hon.70194

BibTeX
@article{Bernardelli2026,
  author = {Bernardelli, A and Carazzai, E and Mion, I and Serafin, N and Ferrarini, I and Krampera, M and Visco, C},
  title = {Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {3},
  doi = {10.1002/hon.70194}
}
Kostenlos starten →